Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


States' Scrutiny Of Supplement Industry Could Climb Following Mid-Terms

Executive Summary

“If this regulatory rollback in Washington continues I think we could see over the next few years AGs start to say, ‘Oh the FTC is not doing what it necessarily should be doing, or 'the FDA is not doing enough,' so these AGs could take over in that space,” says Lori Kalani, co-chair of law firm Cozen O’Connor’s state attorneys general practice. That could happen particularly if Democrats win more AG offices in mid-term elections.


Related Content

Elections Reshape Congress But Not Supplement Industry Regulatory Outlook
NPA Members Get Regulatory Tools In Website Update, Awards At Big Natural
Sweeping Change At FTC May Sweep Away RCT Standard For Health Claims
Criminal Case In PR, FTC Appeal In NY, GNC In India: Health And Wellness Industry News
DMAA, Other Stimulants Cast Shadow Over FDA Supplement Regulation – Study
Supplement Industry Outreach To State Officials Pays Off – Former Maryland AG
N.Y. Herbal Ingredient Testing Got Lost In DNA Swamp – Industry Report


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts